SLC22A12 and chronic kidney disease: In this study, we aimed to investigate whether urate-lowering therapy would improve the course of kidney function in patients with CKD and HUA using dotinurad, a novel selective urate reabsorption inhibitor (SURI) that selectively inhibits the urate transporter 1 (URAT1 / SLC22A12), as an antihyperuricemic agent.